Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34 results about "Toxic shock syndrome" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A life-threatening illness caused due to bacterial toxins.
Substituted heterocyclic compounds and methods of use
The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
Structure-based receptor MIMICS targeted against bacterial superantigen toxins
InactiveUS20050260222A1Improve concentrationDifferent from numberBacterial antigen ingredientsImmunoglobulin superfamilyBacteroidesDecoy
The invention provides therapeutic compositions useful in the treatment of bacterial superantigen mediated conditions, such as Toxic Shock Syndrome. The compositions comprise genetically engineered bifunctional polypeptides containing a specific T-cell receptor binding domain and a specific MHC class 11 receptor binding domain, each targeting non-overlapping epitopes on a superantigen molecule against which they are designed. The anti-superantigen “receptor mimetics” or “chimeras” are rationally designed to recreate the modality of superantigen binding directly to both the TCR and the MHC-II receptor, and are capable of acting as decoys for superantigen binding, effectively out-competing the host T-cell and MHC-II receptors, the natural host receptors.
Owner:THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF ENERGY +1
Substituted heterocyclic compounds and methods of use
The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
Novel heterocycles
InactiveUS20070167413A1Useful in treatmentOrganic active ingredientsBiocideRESPIRATORY DISTRESS SYNDROME ADULTContact dermatitis
The present invention relates to novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel hetereocycles of the general formula (I). Also included is a method of treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.
Owner:ORCHID RES LAB +1
Method for removing toxic shock syndrome toxin-1 in body fluids by adsorption
InactiveUS6315907B1Efficient removalOther chemical processesOther blood circulation devicesWater insolubleSorbent
An adsorbent for toxic shock syndrome toxin-1 (TSST-1) comprising a compound which has a log P value of at least 2.50 wherein P is a partition coefficient in an octanol-water system and which is immobilized on a water-insoluble carrier; a method for removing TSST-1 body fluids by adsorption which comprises bringing a body fluid containing TSST-1 into contact with the adsorbent; an adsorber for TSST-1 comprising an adsorbent packed in a container having an inlet and an outlet for a body fluid and a means for preventing the adsorbent from flowing out of the container; and use of the adsorbent. TSST-1 in body fluids can be efficiently removed by the adsorbent.
Owner:KANEKA CORP
Function epitopes of staphylococcal enterotoxin B (SEB), monoclonal antibodies specifically bound with function epitopes and application of monoclonal antibodies
InactiveCN102757481AAntibacterial agentsImmunoglobulins against bacteriaEpitopeStaphylococcus enterotoxin B
The invention belongs to the technical field of biology, and particularly discloses function epitopes 195SFWYDMMP202, 12HKSSKFTGL20, 18TGLMEN23 and 43QFLFYFIY51 of staphylococcal enterotoxin B (SEB), monoclonal antibodies 4A3 and 3E2 specifically bound with the function epitopes and application of the monoclonal antibodies in the preparation of drugs for treating SEB-induced toxic shock syndrome.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Use of hop acids to inhibit growth of Staphylococcus aureus and prevent toxic shock syndrome
The present invention provides methods, products, and compositions for selectively inhibiting the growth of Staphylococcus aureus without preventing the growth of Lactobacillus species. Specifically, the present invention discloses the use of tetrahydroiso alpha acid or hexahydro beta acid at a concentration effective to inhibit the growth of S. aureus without preventing the growth of Lactobacillus. The inhibition of S. aureus in accordance with the present invention thus provides useful methods, compositions and products such as feminine hygiene products for treating the diseases associated with S. aureus infections and infestations, i.e., toxic shock syndrome, without disrupting the normal bacterial flora in the area of its application.
Owner:MILLERCOORS
Antimicrobial diapers and wet wipes
InactiveUS7105177B1Cheap methodEasily biodegradableCosmetic preparationsBiocideAcid derivativeWet wipe
Diapers and wet wipes for cleansing of infants are made anti-bacterial by the inclusion therein of hop acid derivatives, specifically tetrahydroiso-alpha acid and hexahydro-beta acid. These compounds are effective to inhibit the growth of gram-positive bacteria, and specifically chosen to combat Staphylococcus aureus, a primary factor in toxic shock syndrome in infants.
Owner:MILLERCOORS
Substituted heterocyclic compounds and methods of use
The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, 0 and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
Structure-based receptor MIMICS targeted against bacterial superantigen toxins
InactiveUS7576183B2Improve concentrationDifferent from numberImmunoglobulin superfamilyBacterial antigen ingredientsBacteroidesDecoy
The invention provides therapeutic compositions useful in the treatment of bacterial superantigen mediated conditions, such as Toxic Shock Syndrome. The compositions comprise genetically engineered bifunctional polypeptides containing a specific T-cell receptor binding domain and a specific MHC class II receptor binding domain, each targeting non-overlapping epitopes on a superantigen molecule against which they are designed. The anti-superantigen “receptor mimetics” or “chimeras” are rationally designed to recreate the modality of superantigen binding directly to both the TCR and the MHC-II receptor, and are capable of acting as decoys for superantigen binding, effectively out-competing the host T-cell and MHC-II receptors, the natural host receptors.
Owner:THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF ENERGY +1
Internal menstrual period hygiene product
The invention provides an internal menstrual period hygiene product. An absorbing core body is covered by a waterproof sheath, moisture and secreted fluid of the vagina mucosa cannot be absorbed, menstruation can enter the absorbing core body through an opening of the top of the sheath, thus for a tempon, the hidden health danger of causing a toxic shock syndrome is eradicated, and the hygiene product can be placed in the vagina for a long time. Through the cooperation of the outer edge wide side structure of the top of the sheath and a cannula, the hygiene product can be pushed into the vaginal canal, and the top structure of the sheath can steadily anchor the hygiene product in the vagina for a long time. The cannula can be repeatedly used after being washed, which is beneficial to environmental protection. A stay wire is made of a waterproof material and is prevented from being wet and polluted by urine.
Owner:高文
Uro-genital condition treatment system
InactiveUS20040006024A1Reduced viabilityAccelerate the accumulation processAntibacterial agentsBiocidePenisDisease
The present invention is directed to a system for treating uro-genital conditions. One aspect of this invention involves the treatment system comprising one or more polypeptides with a amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), for treatment of uro-genital conditions. The one or more polypeptides can also be a dimer formed from any of the amino acid sequence above. Uro-genital conditions can include infections, inflammation, or both. In one preferred embodiment of the invention, the uro-genital condition includes infection and / or inflammation of the vagina, vulva, urinary tract, penis, and / or the rectum. In another preferred embodiment of the invention, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment of the invention, the one or more polypeptides are associated with a tampon for preventing toxic shock syndrome. In another preferred embodiment, the one or more polypeptides are associated with a contraceptive for prevention of sexually transmitted diseases or infections. In another preferred embodiment, the one or more polypeptides are associated with a suppository for insertion into the vagina or rectum.
Owner:ZENGEN
Novel pyrimidine carboxamides
InactiveUS20070072876A1Reduce penetrationDecrease in ILSSAntibacterial agentsBiocideContact dermatitisSeptic shock
The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly relates to novel pyrimidine carboxamides of the general formula (I). Also included is a method of prophylaxis or treatment of a pain disorder, immunological diseases, inflammation, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.
Owner:ORCHID RES LAB
Substituted heterocyclic compounds and methods of use
Owner:AMGEN INC
Backflow preventing menstrual cup
A backflow and leakage preventing menstrual cup for collecting menstrual discharge is disclosed. The menstrual cup has a safety feature that prevents backflow of menstrual blood back into vagina and uterus, which minimizes contact with the collected menstrual blood and prevents the risk of infection and toxic shock syndrome (TSS) to the user. This safety feature also stops accidental leakage during use and prevents spillage of menstrual blood when the cup is removed by user. The cup is designed to be easily and quickly emptied.
Owner:VASUDEVA KARINA
Method of preventing T cell-mediated responses by the use of the major histocompatibility complex class II analog protein (map protein) from Staphylococcus aureus
InactiveUS7153515B2Reduce and prevent pathogenicReduce and prevent and deleterious conditionBiocideBacterial antigen ingredientsStaphylococcus cohniiPresent method
A method of immunomodulating the T cell response in Staphylococcal bacteria is provided wherein an effective amount of the Map protein from Staphylococcus aureus is administered to a host to prevent or suppress the T cell response. The present method may be utilized with either the Map protein or an effective subdomain or fragment thereof such as the Map 10 or Map 19 protein. The present invention is advantageous in that suppression or prevention of the T cell response in a host can prevent or ameliorate a wide variety of the pathogenic conditions such as T cell lymphoproliferative disease and toxic shock syndrome wherein the overstimulation of T cells needs to be suppressed or modulated.
Owner:TEXAS A&M UNIVERSITY
Peptides and mimetics for reducing symptoms of toxic shock syndrome and septic shock
InactiveUS20070027088A1Reduce severityAntibacterial agentsBiocideAutoimmune conditionAutoimmune disease
This invention relates to compositions and methods for providing protection against, or reducing the severity of, toxic shock syndrome, septic shock, food poisoning, and autoimmune diseases which are associated with toxin producing bacteria. This invention also relates to methods of using peptides, derivatives, mimetics, and antibodies for the prevention and treatment of toxic shock syndrome, septic shock, food poisoning, and autoimmune diseases, and other related diseases, conditions, and syndromes.
Owner:THE ROCKEFELLER UNIV
Substituted heterocyclic compounds and methods of use
The present invention relates to pyrimidinones and pyridones and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
ActiveUS20190100575A1Reduce the burden onAntibacterial agentsImmunoglobulins against animals/humansDiseaseUpper urinary tract infection
According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a Staphylococcus species target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the Staphylococcus species target antigen with an EC50 of about 10 nM or less, and / or are capable of promoting complement deposition on the Staphylococcus species with an EC50 of about 10 nM. The antibodies of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of a Staphylococcus species is desired and / or therapeutically beneficial, for example, for treating staphylococcal infections including a skin infection, cellulitis, pneumonia, meningitis, urinary tract infection, toxic shock syndrome, endocarditis, osteomyelitis, bacteremia, or sepsis, or for preventing or treating a staphylococcus infection that occurs as a result of a surgical procedure.
Owner:REGENERON PHARM INC
Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
InactiveUS7115268B1Protect against and ameliorate effectAntibacterial agentsFungiSeptic shockPortal pyemia
This invention relates to compositions and methods which provide protection against, or reduce the severity of toxic shock and septic shock from bacterial infections. More particularly it relates to peptides derived from homologous sequences of the family of staphylococcal and streptococcal toxins, which may be polymeric, and carrier-conjugates thereof. The invention also relates to serum antibodies induced by the peptides and carrier-conjugates and their use to prevent, treat, or protect against the toxic effects of most, if not all, of the staphylococcal and streptococcal toxins.The invention also relates to diagnostic assays and kits to detect the presence of staphylococcal and streptococcal toxins, or antibodies thereto. The invention also relates isolated and purified to nucleic acids encoding the peptides of the invention and transformed host cells containing those nucleic acids.
Owner:THE ROCKEFELLER UNIV
Uro-genital condition treatment system
InactiveCN1544461AAvoid Toxic Shock SyndromeAvoid infectionAntibacterial agentsAntimycoticsPenisDisease
The present invention is directed to a system for treating uro-genital conditions. One aspect of this invention involves the treatment system comprising one or more polypeptides with an amino acid sequence including KPV (SEQ ID NO: 1), MEHFRWG (SEQ ID NO: 2), HFRWGKPV (SEQ ID NO: 3), SYSMEHFRWGKPV (SEQ ID NO: 4), for treatment of uro-genital conditions. The one or more polypeptides can also be a dimer formed from any of the amino acid sequences above. Uro-genital conditions can include infections, inflammation or both. In one preferred embodiment of the invention, the uro-genital condition includes infection and / or inflammation of the vagina, vulva, urinary tract, penis, and / or the rectum. In another preferred embodiment of the invention, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment of the invention, the one or more polypeptides are associated with a tampon for preventing toxic shock syndrome. In another preferred embodiment, the one or more polypeptides are associated with a contraceptive for prevention of sexually transmitted diseases or infections. In another preferred embodiment, the one or more polypeptides are associated with a suppository for insertion into the vagina or rectum.
Owner:ZENGEN
Device for detecting toxic shock syndrome toxins and method of making the same
ActiveUS10267792B2Accurate detectionBiological material analysisAnalysis by subjecting material to chemical reactionAntigenToxin
A device for detecting toxic shock syndrome toxins includes a pad and a membrane coupled to the pad. The pad includes first antibodies that include a first particular antibody and a second particular antibody. Each of the first antibodies are associated with toxic shock syndrome toxin one (TSST-1). The first particular antibody is configured to react with a TSST-1 antigen to form an antibody complex. The membrane includes a first zone that includes an immobilized second antibody configured to react with the antibody complex to cause a first indication. The membrane further includes a second zone that includes a third antibody configured to react with the second particular antibody to cause a second indication.
Owner:INT BUSINESS MASCH CORP
Method of preventing T cell-mediated responses by the use of the major histocompatibility complex class II analog protein (map protein) from Staphylococcus aureus
InactiveUS20070092533A1Reducing persistenceReducing virulenceBacterial antigen ingredientsPeptide/protein ingredientsRecurrent infectionsPresent method
A method of immunomodulating the T cell response in Staphylococcal bacteria is provided wherein an effective amount of the Map protein from Staphylococcus aureus is administered to a host to prevent or suppress the T cell response. The present method may be utilized with either the Map protein or an effective subdomain or fragment thereof such as the Map19 protein. The present invention is advantageous in that suppression or prevention of the T cell response in a host can prevent or ameliorate a wide variety of the pathogenic conditions such as toxic shock syndrome and other diseases associated with the T cell-mediated response caused by staphylococcal infection, and is particularly useful in cases where patients have had chronic or recurrent infections from S. aureus or other staphylococcal bacteria.
Owner:BROWN ERIC +2
Substituted heterocyclic compounds and methods of use
The present invention relates to pyrimidinones and pyridones and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
Pyrimidine carboxamides
The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly relates to novel pyrimidine carboxamides of the general formula (I). Also included is a method of prophylaxis or treatment of a pain disorder, immunological diseases, inflammation, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.
Owner:ORCHID RES LAB
Treatment of sepsis and septic shock
PendingCN111971068AOrganic active ingredientsAntiinfectivesALI - Acute lung injuryLow blood pressures
The present invention relates to a composition comprising a mixture of empty liposomes, wherein said mixture of empty liposomes comprises (a) a first empty liposome comprising cholesterol, wherein theamount of cholesterol is at least 30% (weight per weight); and (b) a second empty liposome comprising sphingomyelin, for use in the treatment of sepsis, severe sepsis, septic shock, or prolonged andsevere hypotension, preferably persistent hypotension, for use in the treatment of hypotension, preferably said persistent hypotension, in septic shock, sepsis, severe sepsis, acute respiratory distress syndrome or acute lung injury, or for use in the treatment of toxic shock syndrome in an animal, preferably in a human.
Owner:COMBIOXIN SA
An uro-genital condition treatment system
InactiveCN101249258AAvoid Toxic Shock SyndromeAvoid infectionAntibacterial agentsAntimycoticsDiseasePenis
The invention relates to a dimmer formed by one or more polypeptides for treating uro-genital conditions. Uro-genital conditions can include infections, inflammation, or both. In one preferred embodiment of the invention, the uro-genital condition includes infection and / or inflammation of the vagina, vulva, urinary tract, penis, and / or the rectum. In another preferred embodiment of the invention, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment of the invention, the one or more polypeptides are associated with a tampon for preventing toxic shock syndrome. In another preferred embodiment, the one or more polypeptides are associated with a contraceptive for prevention of sexually transmitted diseases or infections. In another preferred embodiment, the one or more polypeptides are associated with a suppository for insertion into the vagina or rectum.
Owner:ZENGEN
Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
ActiveUS10865236B2Facilitate depositionFacilitates directed killing (cell lysis) of the targeted microbeAntibacterial agentsImmunoglobulins against animals/humansDiseaseSurgical operation
According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a Staphylococcus species target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the Staphylococcus species target antigen with an EC50 of about 10 nM or less, and / or are capable of promoting complement deposition on the Staphylococcus species with an EC50 of about 10 nM. The antibodies of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of a Staphylococcus species is desired and / or therapeutically beneficial, for example, for treating staphylococcal infections including a skin infection, cellulitis, pneumonia, meningitis, urinary tract infection, toxic shock syndrome, endocarditis, osteomyelitis, bacteremia, or sepsis, or for preventing or treating a staphylococcus infection that occurs as a result of a surgical procedure.
Owner:REGENERON PHARM INC
Small molecule inhibitor of MYD88 for therapeutic treatment against alphavirus and staphylococcal enterotoxin infections and toxin exposure
InactiveUS9833437B2Shown some efficacyDemonstrated therapeutic efficacyAntibacterial agentsOrganic active ingredientsTularemiaGram-positive bacterial infections
Owner:UNITED STATES OF AMERICA THE AS REPRESENTED BY THE SEC OF THE ARMY +1
Two flavone glycosides in dandelion and medical use for against Gram-positive bacterium thereof
The present invention relates to flavonoid glycosides isolated from dandelion and capable of preventing and treating Staphylococcus aureus and beta-hemolytic streptococcus infection diseases and their pharmaceutically acceptable salts, their anti-infective medicinal uses, and pharmaceutical compositions containing these compounds. The two novel flavonoid glycoside compounds of the present invention have obvious effects of inhibiting the growth of Staphylococcus aureus and beta-hemolytic streptococcus, and can be expected to be used for the prevention and treatment of boils, pustules and toxic epidermal decomposition caused by the infection of these two. , pneumonia, osteomyelitis, acute myocarditis, endocarditis, meningitis, mastitis, cystitis, pelvic inflammatory disease, urinary tract inflammation, prostatitis, bacteremia, toxic shock syndrome, lymphadenitis, arthritis, pharyngitis , cervicitis, and muscle, skin, urogenital tract, central nervous system abscesses.
Owner:DALI PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com